Table 3.
Antiparkinsonian treatment of PD patients with and without motor complications
| Variable | All patients n = 328 | Motor complications | p‐value | |
|---|---|---|---|---|
| without n = 243 | with n = 85 | |||
| Current antiparkinsonian treatment, n (%) | ||||
| Levodopa summarily | 328 (100%) | 243 (100%) | 85 (100%) | |
| Regular levodopa | 62 (18.9%) | 50 (20.6%) | 12 (14.1%) | .251a |
| CR levodopa | 220 (67.1%) | 181 (74.5%) | 39 (45.9%) | <.0001a |
| Soluble levodopa | 6 (1.8%) | 2 (0.8%) | 4 (4.7%) | .041b |
| Levodopa + | 63 (19.2%) | 19 (7.8%) | 44 (51.8%) | <.0001a |
| COMT inhibitors | ||||
| Dopamine agonists | 103 (31.4%) | 55 (22.6%) | 48 (56.5%) | <.0001a |
| MAO‐B inhibitors | 64 (19.5%) | 46 (18.9%) | 18 (21.2%) | .771a |
| Amantadine | 67 (20.4%) | 32 (13.2%) | 35 (41.2%) | <.0001a |
| Anticholinergics | 9 (27%) | 8 (3.3%) | 1 (1.2%) | .456b |
| Time from PD onset until levodopa treatment, years | ||||
| Mean (SD) | 2.6 (3.6) | 2.6 (3.9) | 2.5 (2.7) | .629c |
| Median (ranges) | 2 (0‐10) | 2 (0‐38) | 2 (0‐13) | |
| Missing | 9 | 6 | 3 | |
| Levodopa daily dose, mg | ||||
| Mean (SD) | 433.5 (221.9) | 390.8 (184.0) | 555.3 (271.8) | <.0001c |
| Median (ranges) | 400 (100‐1300) | 400 (100‐1000) | 500 (100‐1300) | |
| LEDD, mg | ||||
| Mean (SD) | 537.1 (362.7) | 421.7 (222.9) | 865.8 (469.3) | <.0001c |
| Median (ranges) | 450 (75‐2518) | 399 (75‐1120) | 808.5 (100‐2518) | |
| Missing | 1 | 1 | 0 | |
PD, Parkinson's disease; CR, controlled release; SD, standard deviation; LEDD, levodopa equivalent daily dose.
a
chi‐squared test.
b
Fischer's exact test.
c
Mann–Whitney U test.
Statistically significant p‐values after Bonferroni's correction were set at .0041.